Find Reports

Select Report Type

Reimbursement Review

Displaying 1051 - 1075 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Pegaptanib sodium	Macugen	Pegaptanib sodium	cdr_tracking_Macugen.pdf cdr_complete_Macugen_May25-06.pdf	Macular degeneration, age-related	Do not list	Complete	Oct 20, 2005	May 25, 2006	SR0044-000
Quinagolide hydrochloride	Norprolac	Quinagolide hydrochloride	cdr_tracking_Norprolac Resubmission.pdf cdr_complete_Norprolac_Resubmission_May-17-06.pdf	Hyperprolactinemia	List with clinical criteria and/or conditions	Complete	Nov 23, 2005	May 17, 2006	SR0046-000
Tipranavir	Aptivus	Tipranavir	cdr_tracking_Aptivus.pdf cdr_complete_Aptivus_May-17-06.pdf	HIV infection	List with clinical criteria and/or conditions	Complete	Dec 15, 2005	May 17, 2006	SR0047-000
Amlodipine besylate/ atorvasta...	Caduet	Amlodipine besylate/ atorvastatin calcium	cdr_tracking_Caduet.pdf cdr_complete_Caduet_May17-06.pdf	Hypertension/ Dyslipidemia	List with clinical criteria and/or conditions	Complete	Dec 15, 2005	May 17, 2006	SR0048-000
Insulin aspart/insulin aspart ...	NovoMix 30	Insulin aspart/insulin aspart protamine	cdr_complete_NovoMix30_April-26-06.pdf	Diabetes mellitus	Do not list	Complete	Oct 13, 2005	Apr 26, 2006	SR0041-000
Niacin/lovastatin	Advicor	Niacin/lovastatin	cdr_tracking_Advicor.pdf cdr_complete_Advicor_April-26-06.pdf	Hypercholesterolemia and mixed dyslipidemia	List	Complete	Oct 18, 2005	Apr 26, 2006	SR0042-000
Tenofovir disoproxil fumarate	Viread	Tenofovir disoproxil fumarate	cdr_tracking_Viread_Resubmission.pdf cdr_complete_Viread_Resubmission_march2006.pdf	HIV infection	List with clinical criteria and/or conditions	Complete	Aug 11, 2005	Mar 15, 2006	SR0040-000
Omalizumab	Xolair	Omalizumab	cdr_tracking_Xolair_Resubmission.pdf cdr_complete_Xolair_March7-06.pdf	Asthma, severe persistent	Do not list	Complete	Oct 13, 2005	Mar 7, 2006	SR0045-000
Pregabalin	Lyrica	Pregabalin	cdr_tracking_Lyrica.pdf cdr_complete_Lyrica_Jan26-06.pdf	Pain, Neuropathic	Do not list	Complete	Jun 27, 2005	Jan 25, 2006	SR0036-000
Erlotinib	Tarceva	Erlotinib	cdr_tracking_Tarceva.pdf cdr_complete_Tarceva_Dec605.pdf	Cancer, Lung , non-small cell	List with clinical criteria and/or conditions	Complete	Jul 19, 2005	Dec 7, 2005	SR0037-000
Abacavir/lamivudine	Kivexa	Abacavir/lamivudine	cdr_tracking_Kivexa.pdf cdr_complete_Kivexa_Dec605.pdf	HIV infection	List in a similar manner to other drugs in class	Complete	Jul 26, 2005	Dec 7, 2005	SR0038-000
Memantine hydrochloride	Ebixa	Memantine hydrochloride	cdr_tracking_Ebixa.pdf cdr_complete_Ebixa_2005nov23.pdf	Dementia (Alzheimer type), moderate to severe	Do not list	Complete	Dec 21, 2004	Nov 23, 2005	SR0025-000
Quinagolide hydrochloride	Norprolac	Quinagolide hydrochloride	cdr_tracking_Norprolac.pdf cdr_complete_Norprolac_2005Sept28.pdf	Hyperprolactinemia	Do not list	Complete	Dec 16, 2004	Sep 28, 2005	SR0026-000
Atomoxetine hydrochloride	Strattera	Atomoxetine hydrochloride	cdr_tracking_Strattera.pdf cdr_complete_Strattera_2005Sept28.pdf	Attention deficit hyperactivity disorder	Do not list	Complete	Jan 25, 2005	Sep 28, 2005	SR0031-000
Insulin glargine (rDNA origin)	Lantus	Insulin glargine (rDNA origin)	cdr_tracking_Lantus.pdf cdr_complete_Lantus_2005Sept28.pdf	Diabetes mellitus, Type 1 & 2	Do not list	Complete	Feb 11, 2005	Sep 28, 2005	SR0033-000
Laronidase	Aldurazyme	Laronidase	cdr_tracking_Aldurazyme.pdf cdr_complete_Aldurazyme_2005July14.pdf	Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie	Do not list	Complete	Feb 3, 2005	Jul 14, 2005	SR0032-000
Mycophenolate sodium	Myfortic	Mycophenolate sodium	cdr_tracking_Myfortic.pdf cdr_complete_Myfortic_2005July8.pdf	Organ rejection in allogeneic renal transplants, Prophylaxis	List in a similar manner to other drugs in class	Complete	Mar 3, 2005	Jul 8, 2005	SR0034-000
Drospirenone /ethinyl estradio...	Yasmin	Drospirenone /ethinyl estradiol	cdr_complete_Yasmin_June162005.pdf	Contraceptive, oral	List	Complete	Jan 20, 2005	Jun 16, 2005	SR0029-000
Fosamprenavir calcium	Telzir	Fosamprenavir calcium	cdr_tracking_Telzir.pdf cdr_complete_Telzir_June162005.pdf	HIV infection	List in a similar manner to other drugs in class	Complete	Jan 24, 2005	Jun 16, 2005	SR0030-000
Alefacept	Amevive	Alefacept	cdr_tracking_Amevive.pdf cdr_complete_Amevive_2005May26.pdf	Psoriasis, moderate to severe chronic plaque	Do not list	Complete	Nov 16, 2004	May 26, 2005	SR0024-000
Agalsidase beta	Fabrazyme	Agalsidase beta	cdr_tracking_Fabrazyme_Resubmission.pdf cdr_complete_Fabrazyme_Resubmission_may2005.pdf	Fabry Disease	Do not list	Complete	Dec 10, 2004	May 18, 2005	SR0028-000
Voriconazole	VFEND	Voriconazole	cdr_tracking_Vfend_Resubmission.pdf cdr_complete_Voriconazole(Vfend)_April 14-05.pdf	Aspergillosis, Invasive	List with clinical criteria and/or conditions	Complete	Oct 25, 2004	Apr 14, 2005	SR0023-000
Cinacalcet hydrochloride	Sensipar	Cinacalcet hydrochloride	cdr_tracking_Sensipar.pdf cdr_complete_Cinacalcet(Sensipar)_mar23-05.pdf	Secondary hyper-parathyroidism in chronic kidney disease	Do not list	Complete	Aug 20, 2004	Mar 23, 2005	SR0018-000
Eletriptan hydrobromide	Relpax	Eletriptan hydrobromide	cdr_tracking_Relpax.pdf	Migraine	Do not list	Complete	Sep 21, 2004	Mar 23, 2005	SR0021-000
Adalimumab	Humira	Adalimumab	cdr_tracking_Humira.pdf cdr_complete_Humira(adalimumab)Feb11-05.pdf	Arthritis, Rheumatoid	List with clinical criteria and/or conditions	Complete	Sep 24, 2004	Feb 11, 2005	SR0022-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 601 - 602 of 602

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1051 - 1075 of 2138

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Visual Examination Frequency for People Taking Ethambutol for Tuberculosis	Visual Examination Frequency for People Taking Ethambutol for Tuberculosis	May 25, 2021	Health Technology Review	Summary with Critical Appraisal	Completed	RC1343-000
Tuberculosis Screening for People with Chronic Conditions	Tuberculosis Screening for People with Chronic Conditions	May 13, 2021	Health Technology Review	Summary with Critical Appraisal	Completed	RC1345-000
Overview of Formulary Management Practices of Publicly Funded Provincial and Territorial Drug Plans	Overview of Formulary Management Practices of Publicly Funded Provincial and Te…	May 12, 2021	Health Technology Review	Environmental Scan	Completed	ES0354-000
Analysis of FPT Formulary Harmonization: Specialty Care Medications	Analysis of FPT Formulary Harmonization: Specialty Care Medications	May 12, 2021	Health Technology Review	Technology Review	Completed	HD0005-000
Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details		May 6, 2021	Reimbursement Review		Withdrawn	PC0201-000
Polatuzumab Vedotin (Polivy) for DLBCL - Details	10227PolatuzumabDLBCL_fnRec_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_fnCGR_NOREDACT_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_inRec_pERC Chair Approved_Post01Apr2021_final.pdf 10227PolatuzumabDLBCL_PAG Feedback_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_SponsorFeedback_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_PatientFeedback_LC_Final_Redacted.pdf 10227PolatuzumabDLBCL_ClinicianFeedback_CCO_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_Patient COI_LC_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_Combined Clinician COIs EC21Apr2021_final_Redacted.pdf	May 6, 2021	Reimbursement Review		Complete	PC0227-000
Brigatinib (Alunbrig) for Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer - Details	10230BrigatinibALK+NSCLC_fnRec_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_fnCGR_NOREDACT_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_inRec_approvedbyChair_Post01Apr2021_final.pdf 10230BrigatinibALK+NSCLC_PAGFeedback_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_SponsorFeedback_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_PatientFeedback_LCC_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_Combined ClinicianFeedback_EC21Apr2021.pdf 10230BrigatinibALK+NSCLC_Patient COI_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_Combined_COIs EC21Apr2021_final.pdf	May 6, 2021	Reimbursement Review		Complete	PC0230-000
Framework for Drugs for Rare Diseases	es0355-drugs-for-rare-diseases-pw.pdf	May 6, 2021	Horizon Scan	Environmental Scan	Completed	ES0355-000
Electronic Aids to Daily Living	ES0346 Funding and Access to EADLs Final.pdf	May 6, 2021	Health Technology Review	Environmental Scan	Completed	ES0346-000
Treat and Release for Patients Requiring Emergency Medical Services	RC1358 Treat and release - Final.pdf	May 5, 2021	Health Technology Review	Summary with Critical Appraisal		RC1358-000
Interferon Gamma Release Assay for Identifying Latent Tuberculosis Infection in People With Bacillus Calmette-Guérin Vaccination	RC1346 draft Final.pdf	May 5, 2021	Health Technology Review	Summary with Critical Appraisal	Completed	RC1346-000
esketamine hydrochloride	SR0621 Spravato - CDEC Final Recommendation December 18, 2020_for posting.pdf sr0621-spravato-clinical-review-report.pdf sr0621-spravato-pharmacoeconomic-review-report.pdf SR0621_Esketamine_PI Submission.pdf	Apr 30, 2021	Reimbursement Review		Complete	SR0621-000
vedolizumab	SR0647 Entyvio - CDEC Final Recommendation January 22, 2021_for posting.pdf sr0647-entyvio-clinical-economic-review-report.pdf SR0647_Entyvio_PI Submission.pdf	Apr 30, 2021	Reimbursement Review		Complete	SR0647-000
Sonidegib (Odomzo) for Basal Cell Carcinoma - Details	10215SonidegibBCC_fnRec_Post29Apr2021_final.pdf 10215SonidegibBCC_fnEGR_NOREDACT-ABBREV_Post29Apr2021_final.pdf 10215SonidegibBCC_fnCGR_NOREDACT_Post29Apr2021_final.pdf 10215SonidegibBCC_inRec_Post04Mar2021_final.pdf 10215SonidegibBCC_PAGFeedbackSummary_Post29Apr2021_final.pdf 10215SonidegibBCC_SponsorFeedback_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_PatientFeedback_Combined_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_ClinicianFeedback_CCO_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_PatientCOI_Combined_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_ClinicianInput_Combined_COIs Post29Apr2021_final_Redacted.pdf	Apr 29, 2021	Reimbursement Review		Complete	PC0215-000
Niraparib (Zejula) for first line Ovarian Cancer - Details	10224NiraparibOC_fnRec_pERC Chair Approved_Post29Apr2021_final.pdf 10224NiraparibOC_fnEGR_REDACT-ABBREV_Post29Apr2021_final.pdf 10224NiraparibOC_fnCGR_NOREDACT_Post29Apr2021_final.pdf 10224NiraparibOC_inRec_pERC Chair Approved_Post04Mar2021_final.pdf 10224NiraparibOC_PAGFeedbackSummary_Post29Apr2021_final_Redacted.pdf 10224NiraparibOC_SponsorFeedback_Post29Apr2021_final.pdf 10224NiraparibOC_PatientFeedback_OCC_Post29Apr2021_final.pdf 10224NiraparibOC_ClinicianFeedback_CCO_Post29Apr2021_final.pdf 10224NiraparibOC_Patient COI_OCC_Post29Apr2021_final.pdf 10224NiraparibOC_Combined Clinician COIs_Post29Apr2021_final.pdf	Apr 29, 2021	Reimbursement Review		Complete	PC0224-000
CADTH Pharmaceutical Reviews Update — Issue 23		Apr 29, 2021	Reimbursement Review	Pharmaceutical Review Update
apomorphine hydrochloride	SR0650 Kynmobi - CDEC Final Recommendation February 26, 2021_For posting.pdf sr0650-kynmobi-clinical-review-report.pdf sr0650-kynmobi-pharmacoeconomic-review-report.pdf Kynmobi - Patient Group Input_For Posting.pdf	Apr 26, 2021	Reimbursement Review		Complete	SR0650-000
Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dysthymia)	Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dyst…	Apr 26, 2021	Health Technology Review	Summary with Critical Appraisal	Completed	RC1352-000
Onabotulinum Toxin A (Botox) for Spasticity in Patients With Acquired Brain Injury	Onabotulinum Toxin A (Botox) for Spasticity in Patients With Acquired Brain Inj…	Apr 26, 2021	Health Technology Review	Summary with Critical Appraisal		RC1353-000
Unresectable Hepatocellular Carcinoma	Final Report	Apr 21, 2021	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0003-000
nintedanib	SR0654 Ofev - Final CDEC Recommendation February 26, 2021_For Posting.pdf sr0654-ofev-clinical-review-report.pdf sr0654-ofev-pharmacoeconomic-review-report.pdf SR0654 Ofev - Consolidated Patient Input for Posting.pdf	Apr 21, 2021	Reimbursement Review		Complete	SR0654-000
Non-Pharmacological Interventions for the Management of Concussion	de0100-concussion-scoping-summary.pdf	Apr 21, 2021	Health Technology Review	Scoping	Completed	DE0100-000
Rituximab to Treat Primary Membranous Nephropathy	Rituximab to Treat Primary Membranous Nephropathy - Project Protocol Rituximab to Treat Primary Membranous Nephropathy - Report Rituximab to Treat Primary Membranous Nephropathy - Appendix 11	Apr 20, 2021	Health Technology Review	Health Technology Assessment	Completed	HT0032-000 - HS0001-000
ofatumumab	SR0657 Kesimpta - CDEC Final Recommendation March 1, 2021_For posting.pdf sr0657-kesimpta-clinical-review-report.pdf sr0657-kesimpta-pharmacoeconomic-review-report.pdf SR0657 ofatumumab - Patient Input Group - For posting.pdf	Apr 20, 2021	Reimbursement Review		Complete	SR0657-000
Isatuximab (Sarclisa) for Multiple Myeloma - Details	10220IsatuximabMM_fnRec_pERC Chair Approved_Post01Apr2021_final.pdf 10220IsatuximabMM_fnEGR_NOREDACT-ABBREV_Post01Apr2021_final.pdf 10220IsatuximabMM_fnCGR_NOREDACT_Post01Apr2021_final.pdf 10220IsatuximabMM_inRec_pERC Chair Approved_Post4Feb2021_final.pdf 10220IsatuximabMM_PAGFeedbackSummary_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_SponsorFeedback_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_PatientFeedback_MC_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_ClinicianFeedback_CCO_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_Patient_COI_MyelomaCanada_Post01Apr2021_final.pdf 10220IsatuximabMM_Clinician_Combined_COIs_Post_final_Redacted.pdf	Apr 19, 2021	Reimbursement Review		Complete	PC0220-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81